Effect of Obesity on Immune Response to Pneumovax 23

CompletedOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

March 31, 2019

Study Completion Date

May 16, 2019

Conditions
Obesity
Interventions
DRUG

Pneumovax 23

All participants will receive a single 0.5 mL Pneumovax 23 intramuscular vaccine at baseline.

OTHER

Blood tests

All participants will have two 50 milliliter blood draws: at baseline and up to 6 weeks later.

OTHER

Questionnaires

"All participants will answer the following questionnaires:~UCLA Loneliness Scale Questionnaire will be used to measure a difference between the groups.~Perceived Stress Scale-10 Questionnaire will be used to measure a difference between the groups.~Interpersonal Support Evaluation List-12 will be used to measure a difference between the groups Life Orientation Test-Revised will be used to measure a difference between the groups."

Trial Locations (1)

32610

Uf Ctsi Crc, Gainesville

All Listed Sponsors
lead

University of Florida

OTHER

NCT02471014 - Effect of Obesity on Immune Response to Pneumovax 23 | Biotech Hunter | Biotech Hunter